论文部分内容阅读
原发性肝癌是恶性程度最高的肿瘤之一,全球患病率居恶性肿瘤的第5位,病死率居恶性肿瘤的第2位。原发性肝癌亦是我国常见的恶性肿瘤之一,在全球每年新发的原发性肝癌病例中,我国占50%以上。手术切除是原发性肝癌的首选治疗方法,但由于肝癌起病隐匿,发现时常为中晚期,临床仅不到20%的患者有手术切除的机会。因此,TACE已成为中晚期不可切除的原发性肝癌首选的治疗方法。而
Primary liver cancer is one of the most malignant tumors. The global prevalence rate ranks fifth in malignant tumors, and the mortality rate ranks second in malignant tumors. Primary liver cancer is also one of the most common malignancies in China. Among the new cases of primary liver cancer each year in the world, China accounts for more than 50%. Surgical resection is the preferred treatment for primary liver cancer. However, due to the hidden disease of liver cancer, it is often found in the middle and late stages. Clinically, less than 20% of patients have the opportunity to undergo surgical resection. Therefore, TACE has become the preferred treatment for primary hepatocellular carcinoma that is unresectable in the late stage. and